Bristol Myers Squibb, Novo Nordisk, and Ipsen Biopharmaceuticals notified 340B covered entities this week about refunds for charges above 340B ceiling prices.

Three Drug Makers, Including Two with Contract Pharmacy Restrictions, Post 340B Refund Notices

Three drug manufacturers—including two that have imposed conditions on 340B contract pharmacy—posted public notices this week to 340B covered entities about refunds for charges above 340B ceiling prices.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report